Cantor Fitzgerald set a $103.00 price objective on Spark Therapeutics (NASDAQ:ONCE) in a report published on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Other analysts have also recently issued research reports about the company. Royal Bank of Canada cut their price objective on Spark Therapeutics to $64.00 and set a sector perform rating on the stock in a research note on Wednesday, August 8th. UBS Group cut their price objective on Spark Therapeutics from $80.00 to $53.00 and set a neutral rating on the stock in a research note on Wednesday, August 8th. Stifel Nicolaus cut their price objective on Spark Therapeutics from $76.00 to $68.00 and set a buy rating on the stock in a research note on Wednesday, August 8th. BMO Capital Markets cut Spark Therapeutics from an outperform rating to a market perform rating and set a $60.00 price objective on the stock. in a research note on Tuesday, August 7th. Finally, Leerink Swann restated a market perform rating and set a $55.00 price objective (down previously from $74.00) on shares of Spark Therapeutics in a research note on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $65.95.

NASDAQ:ONCE opened at $39.15 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.36 and a current ratio of 10.71. Spark Therapeutics has a one year low of $35.63 and a one year high of $96.59. The stock has a market capitalization of $1.48 billion, a P/E ratio of -5.13 and a beta of 2.25.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The business had revenue of $10.70 million during the quarter, compared to analyst estimates of $27.44 million. During the same quarter last year, the firm posted ($1.90) EPS. The company’s revenue was up 463.2% compared to the same quarter last year. As a group, equities research analysts predict that Spark Therapeutics will post -1.45 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Aperio Group LLC grew its holdings in shares of Spark Therapeutics by 23.5% during the second quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 1,056 shares during the last quarter. Tocqueville Asset Management L.P. grew its holdings in Spark Therapeutics by 2.7% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock worth $3,412,000 after buying an additional 1,075 shares in the last quarter. Amalgamated Bank grew its holdings in Spark Therapeutics by 29.7% in the 2nd quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock worth $397,000 after buying an additional 1,100 shares in the last quarter. Smith Asset Management Group LP grew its holdings in Spark Therapeutics by 39.6% in the 3rd quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock worth $215,000 after buying an additional 1,120 shares in the last quarter. Finally, Capital Fund Management S.A. grew its holdings in Spark Therapeutics by 8.1% in the 2nd quarter. Capital Fund Management S.A. now owns 15,379 shares of the biotechnology company’s stock worth $1,273,000 after buying an additional 1,152 shares in the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Read More: Book Value Per Share in Stock Trading

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.